Lilly's obesity pill draws 1,390 US prescriptions in launch week - Reuters

Lilly's new obesity pill garnered 1,390 US prescriptions during its launch week, according to Reuters. This figure indicates initial uptake for the pharmaceutical company's entry into the competitive and rapidly expanding market for weight-loss medications. The number of early prescriptions provides a preliminary measure of demand and physician adoption for the new treatment. This launch is significant as pharmaceutical companies continue to introduce novel therapies for obesity, a condition affecting millions of Americans. The performance of new drugs like Lilly's pill is closely watched by investors and healthcare providers.